Clinical trials: Dry Age-Related Macular Degeneration
Nonexudative Age Related Macular Degeneration
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- NCT01601483
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MacuCLEAR, Inc.
Dry Age-related Macular Degeneration
Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59
Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over age 60. AMD is classified as wet and dry.
- Trial name
- NCT03144999
- Testing
- AAVCAGsCD59
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Dry Age-related Macular Degeneration
Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- M-CORD IV (NCT06536062)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dry Age-related Macular Degeneration
Microcurrent Stimulation for Dry Age-related Macular Degeneration
Evaluate the safety and efficacy of microcurrent stimulation therapy for patients with dry age-related macular degeneration.
- Trial name
- i-SIGHT (NCT04511936)
- Testing
- i-Lumen AMD
- Sponsor
- i-Lumen Scientific, Inc.
Geographic Atrophy
Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.
- Trial name
- SEATTLE (NCT01802866)
- Testing
- ACU-4429
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- Kubota Vision Inc.
Macular Degeneration
Alprostadil in Maculopathy Study (AIMS)
Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration
- Trial name
- NCT00619229
- Testing
- Alprostadil (prostaglandin E1)
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- UCB Pharma
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Age Related Macular Degeneration
Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
Age-related macular degeneration (AMD) affects 2 million people in France and is the main cause of irreversible blindness in France. All patients initially have an early form of the disease.
- Trial name
- SURViVOR (NCT04697095)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Hospices Civils de Lyon
Dry AMD
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage.
- Trial name
- MACUPREV (NCT03919019)
- Testing
- Macuprev Group
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Dry Age Related Macular Degeneration
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).
- Trial name
- NCT07024732
- Testing
- PST-611
- Where
- 2 sites in France
- Volunteers
- 8 people
- Sponsor
- Eyevensys
Dry Age-Related Macular Degeneration
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
- Trial name
- NCT00950638
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ophthotech Corporation
Advanced Dry Macular Degeneration
Alpha MSH in Ocular Disease
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease.
- Trial name
- NCT03451578
- Testing
- Alpha MSH assay
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Duke University
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
Macular Edema, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT04635800
- Testing
- MHU650
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Geographic Atrophy
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients.
- Trial name
- NCT07602127
- Testing
- AGX-08-L, AGX-08-H, AGX-08-S
- Volunteers
- 24 people
- Sponsor
- Zhongmou Therapeutics
Age-Related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of…
- Trial name
- NCT03178149
- Testing
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Drusen Stage Macular Degeneration
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).
- Trial name
- NCT01272063
- Where
- 4 sites in United States
- Volunteers
- 91 people
- Sponsor
- Carl Zeiss Meditec, Inc.